Quick Answer
Ensysce Biosciences, Inc. reported Cash and Equivalents of $4.31 million for fiscal year 2025.
Ensysce Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $4.31M | +23.1% |
| 2024 | $3.50M | +211.7% |
| 2023 | $1.12M | -64.3% |
| 2022 | $3.15M | -74.3% |
| 2021 | $12.26M | +6215.1% |
| 2020 | $194.2K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.67M | -59.7% | -24.3% |
| June 30, 2025 | $2.21M | +112.0% | -27.5% |
| March 31, 2025 | $3.05M | -10.3% | -12.8% |
| December 31, 2024 | $3.50M | +211.7% | -15.7% |
| September 30, 2024 | $4.15M | +183.6% | +298.1% |
| June 30, 2024 | $1.04M | -72.8% | -69.4% |
| March 31, 2024 | $3.40M | +140.5% | +203.0% |
| December 31, 2023 | $1.12M | -64.3% | -23.3% |
- Ensysce Biosciences, Inc. showed an increase of +23.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Ensysce Biosciences, Inc.’s cash and equivalents has grown by 2119.4% (from $194.2 thousand to $4.31 million).
- The most recent figure is from Ensysce Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: